• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MannKind Corporation - Common Stock (NQ: MNKD )

6.850 +0.550 (+8.73%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MannKind Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
December 20, 2024
Via Benzinga
Topics Stocks
Exposures US Equities
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
December 18, 2024
From MannKind
Via GlobeNewswire
MannKind Shares Are falling Today: What's Going On?
December 16, 2024
MannKind Corporation (NASDAQ: MNKD) are trading lower Monday. The company released its six-month results from its Phase 3 INHALE-1 pediatric diabetes trial. Here's what you need to know. 
Via Benzinga
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
December 16, 2024
From MannKind
Via GlobeNewswire
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
December 11, 2024
From MannKind
Via GlobeNewswire
MannKind (MNKD) Q3 2024 Earnings Call Transcript
November 07, 2024
MNKD earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
November 07, 2024
From MannKind
Via GlobeNewswire
MannKind to Present at 2024 UBS Healthcare Conference
November 05, 2024
From MannKind
Via GlobeNewswire
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
November 04, 2024
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
October 31, 2024
From MannKind
Via GlobeNewswire
Lytham Partners Announces KOL Panels and Participating Companies for its Fall 2024 Investor Conference
September 30, 2024
Phoenix, Arizona and New York, New York--(Newsfile Corp. - September 30, 2024) - Lytham... 
Via Newsfile
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
September 30, 2024
From MannKind
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
September 23, 2024
Via Benzinga
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
September 18, 2024
From MannKind
Via GlobeNewswire
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
September 10, 2024
From MannKind
Via GlobeNewswire
Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday
August 28, 2024
Via Benzinga
MannKind to Present at Upcoming Conferences
August 27, 2024
From MannKind
Via GlobeNewswire
Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
August 14, 2024
From MannKind
Via GlobeNewswire
MannKind (MNKD) Q2 2024 Earnings Call Transcript
August 07, 2024
MNKD earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
August 07, 2024
Conference Call to Begin Today at 9:00 a.m. (ET) 
From MannKind
Via GlobeNewswire
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
July 31, 2024
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
July 30, 2024
From MannKind
Via GlobeNewswire
"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker
June 27, 2024
Our first-ever twin bill. 
Via The Motley Fool
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
June 22, 2024
From MannKind
Via GlobeNewswire
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
June 05, 2024
From MannKind
Via GlobeNewswire
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
May 29, 2024
From MannKind
Via GlobeNewswire
MannKind (MNKD) Q1 2024 Earnings Call Transcript
May 09, 2024
MNKD earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
MNKD Stock Earnings: MannKind Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
MNKD stock results show that MannKind beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
May 08, 2024
Conference Call to Begin Today at 5:00 p.m. (ET) 
From MannKind
Via GlobeNewswire
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
May 06, 2024
From MannKind
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap